747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

• Joal D Beane,
• Yazan Samhouri,
• Brent A Hanks,
• John Hyngstrom,
• Sarah Weiss,
• Heidi Gillenwater,
• Yeonhee Kim,
• J Randolph Hecht,
• Bishwa J Ganguly,
• Hajime Hiraragi,
• Lucy Gong,
• Navid Nikoo

Affiliations

Joal D Beane

Aff1 grid.94365.3d0000000122975165Surgery Branch, National Cancer InstituteNational Institutes of Health Bethesda MD USA

Yazan Samhouri

Medical Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA

Brent A Hanks

Duke University Medical Center, Durham, North Carolina, USA

John Hyngstrom

Surgical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA

Sarah Weiss

1Yale University School of Medicine, New Haven, CT, USA

Heidi Gillenwater

Bristol Myers Squibb, Seattle, WA, USA

Yeonhee Kim

Bristol Myers Squibb, Seattle, WA, USA

J Randolph Hecht

2David Geffen School of Medicine at University of California, Los Angeles, CA, USA

Bishwa J Ganguly

11Lyell Immunopharma, South San Francisco, CA, USA

Hajime Hiraragi

11Lyell Immunopharma, South San Francisco, CA, USA

Lucy Gong

8Lyell Immunopharma, Seattle, WA, USA

Navid Nikoo

8Lyell Immunopharma, Seattle, WA, USA